Connections for use in the treatment of attention deficit / hyperactivity disorder
DE602022012571T2Active Publication Date: 2025-04-023Z EHF
0 Cites 0 Cited by
Patent Information
- Application Number
- DE602022012571
- Authority / Receiving Office
- DE · DE
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2021-01-29
- Filing Date
- 2022-01-28
- Publication Date
- 2025-04-02
- Estimated Expiration
- 2042-01-28
AI Technical Summary
Technical Problem
Current treatments for Attention Deficit/Hyperactivity Disorder (ADHD) have limited efficacy and adverse effects, necessitating the development of alternative therapies that provide clinical benefits with good tolerability.
Method used
A compound of formula (II), such as amlodipine, is administered to reduce ADHD symptoms by targeting the Latrophilin 3 gene mutation, which is associated with ADHD, using a zebrafish model to demonstrate efficacy in reducing hyperactivity and motor impulsivity.
Benefits of technology
Amlodipine effectively reduces ADHD-like behaviors in zebrafish larvae with a Latrophilin 3 gene knock-out, suggesting its potential as a treatment for ADHD with improved tolerability and efficacy.
✦ Generated by Eureka AI based on patent content.
Need to check novelty before this filing date? Find Prior Art
No text content released.